Abstract Library

#3721 No multiple endocrine neoplasia type 1 (MEN1) Patient died from pancreaticoduodenal neuroendocrine tumor – Results from long-term follow-up of the Uppsala model of early diagnosis and treatment

Introduction: Progression of pancreaticoduodenal neuroendocrine tumor (P-NET) disease is the main death cause among MEN1 carriers. Although surgery is the only cure, indications vary substantially between centers. The Uppsala model of MEN1 management encompasses early diagnosis and treatment, aiming at lifelong malignancy prevention with preserved endocrine function. During three decades, all MEN1 patients harbouring P-NETs of at least 1 cm have been considered for surgery.

Conference:

Presenting Author:

Authors: Bajic D, Kjaer J, Welin S, Norlén O, Öberg K,

Keywords: multiple endocrine neoplasia type 1, pancreatic neuroendocrine tumor, indication for surgery, malignancy prevention,

#3514 DLL3 expression and clinico-pathological data in 247 patients with NEN

Introduction: Delta-like protein 3 (DLL3) is currently under clinical investigation as a potential therapeutic target in small cell neuroendocrine lung cancer. Characterization of the levels and patterns of DLL3 expression in other neuroendocrine neoplasms (NEN) is limited.

Conference:

Presenting Author: Clausen M

Authors: Clausen M, Federspiel B, Carstensen F, Suppli M, Kjaer A,

Keywords: DLL3, high-grade NEN,

#1789 FDG-PET is Superior to WHO Grading in Predicting Overall Survival of Patients with Neuroendocrine Tumors: A Prospective Study of 172 Patients

Introduction: Accurate grading of patients with neuroendocrine tumors (NETs) is essential for risk stratification and optimal choice of therapy. Currently, WHO grading is based on histo-pathologically assessed degree of tumor proliferation.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Kjaer A

Authors: Binderup T, Johnbeck C, Loft A, Berthelsen A, Federspiel B,

Keywords: PET, PET/CT, imaging, survival,

#268 Temozolomide as 2.-3. line Treatment of Patients with Poorly Differentiated Neuroendocrine Carcinomas

Introduction: Knowledge of the clinical efficacy of treatment beyond first line of poorly differentiated neuroendocrine carcinomas (PDEC) is sparse. Temozolomide (TMZ) has shown effect in well-differentiated NET.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Olsen I, Federspeil B, Kjaer A, Palnæs Hansen C, Knigge U,

Keywords: PDEC, poorly differentiated carcinomas, temozolomide, second line treatment,